Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349382 | PMC |
| http://dx.doi.org/10.1002/jmv.27945 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Leveraging mobility data to analyze persistent SARS-CoV-2 mutations and inform targeted genomic surveillance.
Elife
January 2025
Institute for Infectious Diseases and Infection Control, Jena University Hospital, Jena, Germany.
Given the rapid cross-country spread of SARS-CoV-2 and the resulting difficulty in tracking lineage spread, we investigated the potential of combining mobile service data and fine-granular metadata (such as postal codes and genomic data) to advance integrated genomic surveillance of the pandemic in the federal state of Thuringia, Germany. We sequenced over 6500 SARS-CoV-2 Alpha genomes (B.1.
View Article and Find Full Text PDFHigh performance COVID-19 screening using machine learning.
Tunis Med
January 2025
Laboratory of viruses, vectors and hosts: LR20IPT10, Institut Pasteur de Tunis, University of Tunis El Manar, 13, Place Pasteur, 1002 Tunis Belvédère, Tunisia.
Since the World Health Organization declared the Coronavirus Disease 2019 (COVID-19) pandemic as an international concern of public health emergency in the early 2020, several strategies have been initiated in many countries to prevent healthcare services breakdown and collapse of healthcare structures. The most important strategy was the increased testing, diagnosis, isolation, contact tracing to identify, quarantine and test close contacts. In this context, finding a rapid, reliable and affordable tool for COVID-19 screening was the main challenge to address the pandemic.
View Article and Find Full Text PDFHuman HKU1-reactive CD4 T cells are enriched for cytolytic potential that persists in older adults.
J Infect Dis
January 2025
David H. Smith Center for Vaccine Biology and Immunology, Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA.
The emergence of SARS-CoV-2 increased interest in cellular immunity established by infections with human coronaviruses (HCoVs). Using PBMC from a cohort of human subjects collected prior to 2019, we assessed the abundance and phenotype of these CD4 T cells using cytokine Elispot assays. Unexpectedly, cytotoxic potential was uniquely enriched amongst HKU1-reactive CD4 T cells, as measured by quantification of granzyme producing cells.
View Article and Find Full Text PDFSystematic Molecular Influenza A/B Screening Upon Hospital Admission in Belgium, January-April 2022: Positivity Ratios and Viral Loads According to Symptomatology, Age, and Vaccination Status.
J Med Virol
January 2025
Department of Laboratory Medicine, Ziekenhuis aan de Stroom, Antwerp, Belgium.
Three hospitals implemented molecular point-of-care tests (POCTs) to screen patients for SARS-CoV-2 infection upon admission during the 2021/2022 influenza season, which in Belgium lasted from January to April 2022. The samples were simultaneously tested for influenza A/B. Influenza positivity at admission was examined in relation to patient characteristics and symptomatology.
View Article and Find Full Text PDFAssessment of clinical characteristics and mortality in patients hospitalized with SARS-CoV-2 from January 2022 to November 2022, when Omicron variants were predominant in the United States.
Curr Med Res Opin
January 2025
Pfizer Inc., US Medical Affairs, New York, NY, USA.
Objective: To describe the demographic/clinical characteristics, treatment patterns, and mortality among patients hospitalized with COVID-19 during Omicron predominance by immunocompromised and high-risk status.
Methods: Retrospective observational study of patients hospitalized with COVID-19 between January 1, 2022 and November 30, 2022, using data from the Optum de-identified Clinformatics® Data Mart Database. Patient demographic/clinical characteristics, treatments, mortality and costs, were assessed, during the emergence of BA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!